相关实验视频
Updated: Sep 10, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
长期用泰迪索利德抑制治疗期间的外围神经病变:一个病例系列
Tomaso Beringheli1,2,3, Clément Javaux1,2, Sandrine Roux1,2
1Centre de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon, www.crioac-lyon.fr), Hospices Civils de Lyon, Lyon, France.
长期使用泰迪索利德可能会导致周围神经病变,特别是在糖尿病患者中. 在长期治疗Gram阳性感染时监测神经学不良事件.
科学领域:
- 传染性疾病
- 神经学
- 药理学
背景情况:
- 在慢性格拉姆阳性感染中,Tedizolid比linezolid具有潜在的血液耐受性.
- 对于延长使用,需要进一步调查tedizolid的神经毒性风险.
研究的目的:
- 在治疗慢性植入物相关感染时报告神经学不良事件.
- 评估与长期使用泰迪索利德相关的外围神经病变风险.
主要方法:
- 患者出现与tedizolid相关的神经不良事件的回顾性病例系列.
- 对外围神经病变的临床表现,风险因素和结果的分析.
主要成果:
- 经过平均12. 4个月的泰迪索利德治疗,有5名患者出现了外围神经病变.
- 由于毒性,四名患者先前停止了linezolid治疗;三名患者有额外的神经病变风险因素.
- 在大多数病例中,肌电图证实了轴突感官多神经病变;三名患者在停止服用泰迪索利德后康复.
结论:
- 长期使用泰迪索利德可能会导致神经周围毒性.
- 在长期服用泰迪索利德的患者中,对神经病变的监测至关重要,特别是那些处于危险阶段的患者.
更多相关视频
09:39Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
Published on: February 13, 2018
09:34An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
相关概念视频
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Desensitization and Tachyphylaxis
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Peripheral Artery Disease IV: Nursing Management
Peripheral Artery Disease I: Introduction